• The company spent the pandemic years in the wilderness as blood donors stayed away and their accounting for brokerage from pharma programs was overly aggressive.
• But the company kept on sweeping up plasma centers as customers, laying the groundwork for an eventual recovery.
• That recovery is now here and has legs, but the question remains whether the company can move beyond plasma centers.
• Looking for more investing ideas like this one? Get them exclusively at SHU Growth Portfolio. Learn More »

The Recovery At PaySign Has Legs (NASDAQ:PAYS)